Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy
Authors:
- 2 May 2024
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (6) , 1845-1853
Abstract
Objective To investigate the metabolic changes during therapy of tocilizumab (TCZ) and methotrexate (MTX) in non-diabetic rheumatoid arthritis (RA) patients and for the first time explore the associations between metabolic parameters and serum YKL-40 (sYKL-40) levels. Methods We enrolled active non-diabetic RA patients who were refractory to MTX. Patients received intravenous TCZ (8 mg/kg) once every 4 weeks combined with MTX for 24 weeks. Metabolic parameters and sYKL-40 levels were measured before TCZ infusion at baseline, week 4, week 12, and week 24. Correlations were assessed by the Spearman’s rank correlation analysis. Results A total of 91 non-diabetic RA patients were enrolled in this study. At week 24, we observed a significant elevation in body mass index (BMI), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) levels. In contrast, there was a significant decrease in TC/HDL‑C ratio. No apparent changes in insulin resistance were found. Additionally, we detected a significant reduction in sYKL-40 levels during the study. At week 24, changes in sYKL-40 levels showed a significant negative correlation (r = -0.334, p = 0.002) with changes in TC levels. Conclusion The combined therapy of TCZ and MTX resulted in a significant increase in BMI and lipid levels, while an evident decrease in the TC/HDL‑C ratio and sYKL-40 levels in RA patients. Additionally, there was a significant correlation between the decrease in sYKL-40 levels and the increase in TC levels during treatment with TCZ and MTX. Key Points • Lipid levels elevated significantly and sYKL-40 levels decreased obviously after therapy of TCZ combined with MTX in Chinese RA patients. • There was a significant correlation between the increase in TC levels and the decrease in sYKL-40 levels during treatment with TCZ and MTX in RA patients.Keywords
Funding Information
- Science and Technology Innovation Talents in Universities of Henan Province (LHGJ20190062)
This publication has 34 references indexed in Scilit:
- The effect of non–TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritisAutoimmunity Reviews, 2018
- Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritisJournal of Cachexia, Sarcopenia and Muscle, 2017
- Rheumatoid arthritis and metabolic syndromeNature Reviews Rheumatology, 2014
- Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockadeClinical Rheumatology, 2014
- Changes in lipid levels with inflammation and therapy in RA: a maturing paradigmNature Reviews Rheumatology, 2013
- Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: A 16-week comparative studyCytokine, 2012
- Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal childrenMetabolism, 2012
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosisInflammation Research, 2006
- YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistanceInflammation Research, 2006